Joe Jimenez

Latest Headlines

Latest Headlines

Novartis CEO shopping for bolt-on deals at $4B, tops

Yesterday, analysts predicted that 2013 would be the year Big Pharma would take bigger bites from the M&A apple. But don't count Novartis ($NVS) among the crowd willing to pay $10 billion or more for the right company. CEO Joe Jimenez says his appetite is limited to $4 billion at most.

Novartis grabs EU committee support for first meningitis B vaccine

Novartis has scored a key endorsement for one of the brightest stars from its vaccines division. The European Union's Committee for Medicinal Products for Human Use (CHMP) backed approval of Bexsero, the Swiss drug giant's ($NVS) meningitis B vaccine that could become the first such shot to hit the market if the European Commission follows the CHMP's advice.

Novartis plant delay, vaccine woes steal spotlight

Manufacturing woes, actual and potential, overshadowed Novartis' ($NVS) earnings announcement today. In the realm of the actual, the company's Lincoln, NE, plant won't resume production by year's end as expected, because fixing problems there is taking longer than expected.

Novartis CEO: No on megadeals, yes on medium-sized buyouts

The acquisition strategy, though, will have to be tailored to continue the company's dividend support plan.

Novartis CEO: No on megadeals, yes on dividend

Novartis ($NVS) CEO Joe Jimenez isn't shy about holding up a "warning" sign. In an interview with Switzerland's Sonntags Zeitung over the weekend, Jimenez once again reminded folks to expect no fireworks from Novartis in the near term.

Coca-Cola coaches African health officials on drug-and-vax distribution

Novartis ($NVS) CEO Joe Jimenez is only one pharma executive who figures the industry can learn a thing or two from consumer goods.

Novartis chief to employees: We need a quality reboot

In the course of 9 months, the company received a three-plant FDA warning letter, closed its key OTC plant and had to tell shareholders that revenues slid 4% because the manufacturing mess kept it from having its most popular consumer products.

Shire CEO sees consumer-goods strategies in pharma's future

We're wondering whether Shire CEO Angus Russell and Novartis chief Joe Jimenez were separated at birth. Sure, the two companies are worlds apart, size-wise. But the two CEOs both see pharma's future--and the future of their own companies--as more customer-oriented and nimble, informed by strategies long used in the consumer-goods business.

Multibillion-dollar R&D strategy is paying off for Novartis

Novartis CEO Joe Jimenez managed to impress the Wall Street crowd today with some solid numbers for the second quarter.

Novartis blueprints $550M Swiss drug plant after layoffs backlash

Novartis CEO Joe Jimenez has a new answer to his critics in Switzerland, where the drug giant's major layoff plans ignited a wave of protests against the company.